Clinical trials: Dermatitis Atopic
Atopic Dermatitis
0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis
This study will determine the safety and efficacy of diluted bleach bath solution as final rinse on the reduction of Staphylococcus aureus colonization among children and adult Filipinos with mild to moderate atopic dermatitis..
- Trial name
- NCT02241174
- Testing
- Sodium Hypochlorite
- Where
- Philippines
- Volunteers
- healthy volunteers welcome
- Sponsor
- Makati Medical Center
Atopic Dermatitis, Hidradenitis Suppurativa
Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions
Investigators will sample the skin and blood of patients with chronic skin conditions (including but not limited to atopic dermatitis (AD), contact dermatitis, hidradenitis suppurativa (HS), and psoriasis) to study the expression…
- Conditions
- Atopic Dermatitis, Hidradenitis Suppurativa, Contact Dermatitis, Psoriasis
- Trial name
- NCT03198390
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Atopic Diathesis, Eczema-prone Skin
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis
The aim of this study is to compare the efficacy and tolerability and of a cosmetic product to one that is already available on the market (benchmark product).
- Trial name
- NCT05807113
- Testing
- Atopi intensive care BNO 3731, Benchmark product
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Dermatitis, Atopic
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
Part A To measure and compare the amount of study drug in the blood after a single 200 mg dose of study drug given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions To measure and…
- Trial name
- NCT04065633
- Testing
- P3-Fast, Comm-Fast, Vari-Fast
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers, Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to…
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Trial name
- 3 (NCT01428297)
- Testing
- BPR277 ointment (controlled application), BPR277 ointment, BPR277
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate…
- Trial name
- NCT05859724
- Testing
- NM26-2198
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Yellow Jersey Therapeutics AG
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
- Trial name
- NCT06787586
- Testing
- ATTO-1310
- Where
- 17 sites in United States, Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Atopic Dermatitis, Skin Inflammation
Detection of Skin Epithelial Barrier in Patients With Allergic Skin Disorders
The primary function of epithelial tissues is to form a barrier between the body and the external environment, in order to protect the internal tissues from environmental stresses, by minimizing water loss and preventing the…
- Trial name
- NCT03581747
- Testing
- Nevisense
- Where
- Switzerland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Swiss Institute of Allergy and Asthma Research
Moderate to Severe Atopic Dermatitis
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD).
- Trial name
- NCT07558668
- Testing
- SYX-5219 Oral Capsule
- Where
- 14 sites in United States, Bulgaria and 4 more
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Sitryx Therapeutics Ltd
Immune Deficiency, Immune Dysregulation Disorder
Allergy and Immunology Natural History Study
This protocol is a natural history study designed to evaluate subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or Immune Dysregulation.
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Trial name
- NCT05584488
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Smallpox, Atopic Dermatitis
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with a history of mild to moderate Atopic Dermatitis.
- Trial name
- NCT00389103
- Testing
- MVA (smallpox vaccine)
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dermatitis, Atopic, Pruritus
Study to Evaluate ASN008 Topical Gel (TG)
This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects
- Conditions
- Dermatitis, Atopic, Pruritus, Dermatitis Eczema
- Trial name
- NCT03798561
- Testing
- ASN008 TG
- Where
- 5 sites in United States, Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Asana BioSciences
Atopic Dermatitis
LEO 29102 Single and Multiple Dose Study by Dermal Application
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects.
- Trial name
- NCT00891709
- Testing
- LEO 29102
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Atopy, Atopic Dermatitis
Inhibitory Receptors in Eosinophils of Atopic Subjects
The purpose of this study is to analyze the expression and activity of inhibitory molecules on eosinophils obtained from allergic subjects.
- Conditions
- Atopy, Atopic Dermatitis, Asthma, Allergic Rhinitis
- Trial name
- NCT01489293
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Atopic Dermatitis (AD)
A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects
The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).
- Trial name
- NCT04056130
- Testing
- KBL697
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- KoBioLabs
Atopic Dermatitis, Eczema Herpeticum
Interferon Responses in Eczema Herpeticum
Atopic dermatitis (AD) is a chronic skin disorder characterized by recurrent viral skin infections. A small subset of patients with AD suffer from disseminated viral infections, e.g., eczema herpeticum (ADEH+), after herpes…
- Conditions
- Atopic Dermatitis, Eczema Herpeticum, Herpes Simplex Infections, Eczema Vaccinatum
- Trial name
- ADRN-01 (NCT01429311)
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis (AD)
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
The purpose of this 14-day, two phase clinical study is to test the tolerance of a new over-the-counter moisturizing balm on subjects with eczema.
- Trial name
- NCT02357940
- Testing
- Experimental Product
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis
This proof of concept study aims to assess in patients suffering from atopic dermatitis if polymeric microparticles reach the pilosebaceous follicles of inflamed skin.
- Trial name
- MicroIskin (NCT02369432)
- Testing
- Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy
- Where
- France
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Urticaria, Atopic Dermatitis
Platelet Activation in Chronic Inflammatory Skin Diseases
Platelets are blood cells that are important in coagulation of the blood. These cells have recently been shown to play a role in a number of other biologic processes, for example inflammation.
- Trial name
- NCT01759693
- Testing
- Blood sampling
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants
The primary objective of the study is to evaluate the pharmacokinetics of rocatinlimab after single subcutaneous (SC) administration in healthy Chinese participants.
- Trial name
- NCT06214481
- Testing
- Rocatinlimab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amgen